Amgen reports fiscal Q1 2026 results: revenue $8.62B, up 6% from a year earlier

Amgen filed a Form 8-K with the SEC on Apr 30, 2026, 4:03 PM ET, reporting an event dated Apr 30, 2026. It covers Item 2.02 (Results of Operations and Financial Condition); Item 9.01 (Financial Statements and Exhibits). The results cover fiscal Q1 2026 (quarter ended Mar 31, 2026); figures below are from the company's XBRL financial data filed with the SEC.

• Revenue: $8.62B (+5.8% from $8.15B a year earlier)
• Operating income: $2.67B (+126.3% from $1.18B a year earlier)
• Net income: $1.82B (+5.1% from $1.73B a year earlier)
• Diluted EPS: $3.34 (+4.4% from $3.20 a year earlier)
• Form 8-K accepted by EDGAR Apr 30, 2026, 4:03 PM ET
• Accession number 0000318154-26-000054

SEC filing 8-K · accession 0000318154-26-000054 · sec.gov ↗